Ironwood Pharmaceuticals, Inc. (IRWD)
IRWD Stock Price Chart
Explore Ironwood Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze IRWD price movements and trends.
IRWD Company Profile
Discover essential business fundamentals and corporate details for Ironwood Pharmaceuticals, Inc. (IRWD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Feb 2010
Employees
253.00
Website
https://www.ironwoodpharma.comCEO
Thomas A. McCourt
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IRWD Financial Timeline
Browse a chronological timeline of Ironwood Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.08, while revenue estimate is $74.22M.
Earnings released on 7 Aug 2025
EPS came in at $0.14 surpassing the estimated -$0.02 by +800.00%, while revenue for the quarter reached $85.24M , beating expectations by +9.53%.
Earnings released on 7 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.05 by -180.00%, while revenue for the quarter reached $41.14M , missing expectations by -42.08%.
Earnings released on 27 Feb 2025
EPS came in at $0.02 falling short of the estimated $0.10 by -80.00%, while revenue for the quarter reached $90.55M , beating expectations by +35.10%.
Earnings released on 7 Nov 2024
EPS came in at $0.02 falling short of the estimated $0.08 by -75.00%, while revenue for the quarter reached $91.59M , missing expectations by -0.96%.
Earnings released on 8 Aug 2024
EPS came in at -$0.01 falling short of the estimated $0.15 by -103.61%, while revenue for the quarter reached $94.40M , missing expectations by -11.78%.
Earnings released on 9 May 2024
EPS came in at -$0.02 falling short of the estimated $0.18 by -111.11%, while revenue for the quarter reached $74.88M , missing expectations by -29.23%.
Earnings released on 15 Feb 2024
EPS came in at -$0.01 falling short of the estimated $0.21 by -104.76%, while revenue for the quarter reached $117.55M , beating expectations by +0.06%.
Earnings released on 9 Nov 2023
EPS came in at $0.09 falling short of the estimated $0.16 by -43.75%, while revenue for the quarter reached $113.74M , beating expectations by +0.75%.
Earnings released on 8 Aug 2023
EPS came in at $0.31 surpassing the estimated $0.25 by +24.00%, while revenue for the quarter reached $107.38M , beating expectations by +3.54%.
Earnings released on 4 May 2023
EPS came in at $0.25 surpassing the estimated $0.24 by +4.17%, while revenue for the quarter reached $104.06M , beating expectations by +3.64%.
Earnings released on 16 Feb 2023
EPS came in at $0.27 matching the estimated $0.27, while revenue for the quarter reached $107.20M , missing expectations by -0.78%.
Earnings released on 3 Nov 2022
EPS came in at $0.28 surpassing the estimated $0.27 by +3.70%, while revenue for the quarter reached $108.64M , missing expectations by -0.47%.
Earnings released on 4 Aug 2022
EPS came in at $0.21 falling short of the estimated $0.30 by -30.00%, while revenue for the quarter reached $97.23M , missing expectations by -6.10%.
Earnings released on 5 May 2022
EPS came in at $0.21 falling short of the estimated $0.26 by -19.23%, while revenue for the quarter reached $97.53M , beating expectations by +0.94%.
Earnings released on 17 Feb 2022
EPS came in at $0.27 falling short of the estimated $0.35 by -22.86%, while revenue for the quarter reached $117.13M , beating expectations by +6.31%.
Earnings released on 4 Nov 2021
EPS came in at $0.33 surpassing the estimated $0.31 by +6.45%, while revenue for the quarter reached $103.75M , missing expectations by -2.51%.
Earnings released on 5 Aug 2021
EPS came in at $0.34 surpassing the estimated $0.23 by +47.83%, while revenue for the quarter reached $104.03M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at $0.24 surpassing the estimated $0.21 by +14.29%, while revenue for the quarter reached $88.85M , missing expectations by -1.47%.
Earnings released on 17 Feb 2021
EPS came in at $0.36 surpassing the estimated $0.27 by +33.33%, while revenue for the quarter reached $116.68M , beating expectations by +4.23%.
Earnings released on 5 Nov 2020
EPS came in at $0.23 surpassing the estimated $0.15 by +53.33%, while revenue for the quarter reached $103.47M , beating expectations by +53.33%.
IRWD Stock Performance
Access detailed IRWD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.